A new report published in the journal Cannabis and Cannabinoid Research presents an overview of the clinical findings concerning the effectiveness of cannabidiol in the treatment of anxiety.

The psychedelic drug industry already has a large footprint in healthcare. And it is growing in literally every direction.

A bill to federally legalize marijuana and promote social equity in the industry was reintroduced in the House.

A top U.S. health official on Wednesday touted the therapeutic potential of psychedelics like psilocybin and MDMA.

It may only be a matter of time before psychedelics become a go-to treatment for millions suffering with some sort of mental illness.

From jobs to tax revenue to commercial real estate, the marijuana industry has a large – and growing – impact on the broader economy in the United States.

There’s been a substantial proof psychedelics can help with issues such as depression, anxiety, addiction, obsessive compulsive disorder, and obesity.

The bill passed 6-0 and has garnered bipartisan support.

Research is proving the potential psychedelics hold when it comes to healing mental health. Now, investors are looking to cash in.